ICU Medical (NSDQ:ICUI) shares gained almost 3% this morning despite a 4th-quarter profit decline of nearly 31%, as investors reacted to above-expectation adjusted earnings per share.
ICU Medical Inc.
Shire adds Pervasive Therapeutics to regenerative portfolio | Wall Street Beat
Standard & Poor’s gives Medtronic an A+ | Wall Street Beat
Standard & Poor’s Ratings Services affirmed Medtronic’s (NYSE:MDT) long-term debt’s “A+” rating yesterday, after the med-tech titan announced another debt offering.
The rating agency said its view of Medtronic’s senior unsecured notes and its stable rating outlook “reflect the company’s ‘strong’ business risk profile and ‘modest’ financial risk profile.”
McKesson’s Q3 beats The Street, pays $918M for Canadian pharmacy biz | Earnings Roundup
McKesson (NYSE:MCK) shares got a bump in after-hours trading yesterday when it reported strong 3rd-quarter results and announced the $918 million acquisition of a chain of independent pharmacies in Canada.
Baxter boosts forecast after strong Q3 | Earnings Roundup
Baxter International Inc. (NYSE:BAX) said it now expects to post earnings of at least $4.29 per share this year, after logging strong third-quarter results.
Edwards’ Q3 sales rise 18 percent, profits jump 8 percent | Earnings Roundup
Edwards Lifesciences (NYSE:EW) can’t seem to get a break on Wall Street, where its share price slipped 3.4 percent today despite growth for its top and bottom lines.
The Irvine, Calif.-based heart valve maker missed The Street’s earnings forecast by a mere penny, but that was enough to send its shares down to a $67.79 close.
Occlutech CEO: St. Jude’s patent suit against me “amazing and quite shocking” | Legal News
A patent spat between St. Jude Medical (NYSE:STJ) and Occlutech GmbH that morphed into a personal lawsuit against Occlutech CEO Tor Peters was dismissed by a German court, prompting Peters to call the suit "amazing and quite shocking."
St. Jude inherited the case, involving intravascular occlusion devices, after it acquired AGA Medical for more than $1 billion last year.
Abbott’s “beat & raise” Q2 bores Wall Street | Earnings Roundup
There’s no pleasing some people. Abbott (NYSE:ABT) shares were down on Wall Street today, despite the health care products giant reporting strong second-quarter sales and earnings figures — including a nearly 100 percent top-line surge for its coronary stents business.
Neuros Medical touts pain-blocking device study | Research roundup
Neurotechnology startup Neuros Medical Inc. reported encouraging results from the first in-human study of its device that blocks pain for amputees.
The Willoughby, Ohio-based company said that four of five patients in the study reported that its device reduced their pain to “zero,” according to a statement from the company.
ICU Medical trumps RyMed in patent decision
UPDATED Dec. 22, 12:35 p.m.
ICU Medical Inc. (NSDQ:ICUI) landed a patent victory over RyMed Technologies Inc.
An eight-person jury in the U.S. District Court for Delaware found that technology employed in Franklin, Tenn.-based RyMed’s InVision Plus IV connector infringes upon two patents owned by ICU Medical.
Bottom line dips for ICU Medical despite Q4 sales boost
ICU Medical Inc. (NSDQ:ICUI) posted fourth-quarter sales of $69.8 million for the three months ended Dec. 31, 2009, up 23 percent compared with $56.7 million during the same period last year. Net income fell 18 percent to $7.4 million, compared with $9 million during Q4 2008: